Accurate & sensitive tools for Breast Cancer research & clinical applications
Cancers of the breast represent the most prevalent type of neoplastic disease in women and are the number two cause of cancer related deaths amongst women behind lung cancer. In contrast, the incidence of breast cancer in men is about 100 fold less.
Proteome Sciences has a range of mass spectrometry based assays for human breast cancer research, targeting key signaling proteins associated with the disease. The Breast Cancer ER Phosphoryation 6-plex Assay simultaneously measures multiple phosphorylation sites of human Estrogen Receptor alpha, and the Breast Cancer Signaling Receptor 3-plex Assay measures multiple protein molecules in breast cancer associated signaling pathways.
| Applications | Sample Types | Species | Analysis Method |
| Drug discovery | Cultured cells | Human | AQUA_SRM Peptide Mass Spectrometry |
| *Clinical analysis, early detection/prognostic | *Biopsy tissues | Human | AQUA_SRM Peptide Mass Spectrometry |
* In Development
Estrogen receptor is heavily implicated in the pathology of breast cancer, with over 70% of tumors over-expressing ERa. Disruption of normal ERa function can lead to perturbation of cell cycle control, apoptosis and DNA repair mechanisms, all of which are characteristic of the progression of breast cancer disease.
The phosphorylation state of ERa regulates its activity and appears to be associated with breast cancer progression and response to anti-estrogen therapies such as Tamoxifen.
Breast Cancer ER Phosphorylation 6-plex Assay offers:
In addition to the dysregulation of Estrogen Receptor alpha, numerous other signaling receptors and their associated pathway proteins have been identified in breast cancer. Subtle changes (post-translational modifications) in these proteins act as switches promoting tumor growth and inhibiting host responses. Improving management of breast cancer requires a more detailed understanding of the signaling pathways active in each individual tumor. Current methods require immunological staining of biopsy sections and suffer from lack of antibody specificity and the inability to multiplex for several proteins and post-translational modifications in a single test. Proteome Sciences is working with two leading US cancer research centers to develop a biomarker panel which simultaneously measures three key signaling receptor proteins, Estrogen receptor alpha, Progesterone Receptor and HER2, which are often used to classify the stage and metastatic potential of breast tumors.
Breast Cancer Pathway 3-plex Assay offers:
Also see our proprietary Cancer Pathways Assays
| Breast Cancer 6-plex Assay | Breast Cancer 3-plex Assay |
| p-ERa (Ser 154) | Estrogen Receptor alpha |
| p-ERa (Ser 167) | Progesterone Receptor |
| p-ERa (Ser 294) | HER2 |
| p-ERa (Tyr 537) | |
| p-ERa (Ser 559) | |
| Total ERa |
